72 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
, but not limited to, communications by email, regular mail, telephone, fax, instant message and social media platforms whether or not in existence at the date
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
for social security contribution in any jurisdiction) that the Option Holder’s Employer is liable to pay as a result of any Taxable Event (or which
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
(2) of Schedule 5 to ITEPA 2003;
“Employer NICs”
any secondary class 1 (employer) National Insurance contributions (or any similar liability for social
8-K
EX-10.4
u35i kljs8r3
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
7cj7u0o1r8qb6x0
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
lpozvt1wi
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
qs5iaw
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.01
7cjd2y7l
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-10.1
w4fd6q2ko 872djpk0
16 Dec 20
Departure of Directors or Certain Officers
5:01pm
S-3ASR
EX-1.2
vps1x
10 Aug 20
Automatic shelf registration
5:01pm